152 related articles for article (PubMed ID: 29344324)
1. Treatment of Lateral Periorbital Lines with Different Dilutions of IncobotulinumtoxinA.
Muti GF; Basso M
J Clin Aesthet Dermatol; 2017 Sep; 10(9):27-29. PubMed ID: 29344324
[No Abstract] [Full Text] [Related]
2. Evaluating the Effect of Incobotulinumtoxin A for Glabellar, Forehead, and Crow's Feet Lines Using A High Dilution.
Barbarino SC; van Loghem JAJ; Burgess CM; Corduff N
J Clin Aesthet Dermatol; 2021 Aug; 14(8):34-40. PubMed ID: 34840655
[TBL] [Abstract][Full Text] [Related]
3. A Prospective, Neurophysiologic Comparative Study to Assess the Efficacy and Duration of Effect of IncobotulinumtoxinA and AbobotulinumtoxinA in the Treatment of Crow's Feet.
Saybel A; Artemenko A; Nikitin S; Kurenkov A
J Drugs Dermatol; 2015 Nov; 14(11):1291-6. PubMed ID: 26580879
[TBL] [Abstract][Full Text] [Related]
4. IncobotulinumtoxinA Is an Effective and Well-Tolerated Treatment for Upper Facial Lines: Results From an Open-Label Extension Period of a Phase III Study.
Trevidic P; Connolly SA; Biwer B; Ellers-Lenz B; Harrington LS; Kestemont P; Noah EM; Sattler G; Weissenberger P; Kerscher M
Dermatol Surg; 2017 Dec; 43 Suppl 3():S285-S292. PubMed ID: 33065954
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From a Randomized, Double-Blind, Placebo-Controlled, Phase III Study.
Kerscher M; Rzany B; Prager W; Turnbull C; Trevidic P; Inglefield C
Dermatol Surg; 2015 Oct; 41(10):1149-57. PubMed ID: 26359996
[TBL] [Abstract][Full Text] [Related]
6. A prospective rater- and subject-blinded study comparing the efficacy of incobotulinumtoxinA and onabotulinumtoxinA to treat crow's feet: a clinical crossover evaluation.
Muti G; Harrington L
Dermatol Surg; 2015 Jan; 41 Suppl 1():S39-46. PubMed ID: 25548844
[TBL] [Abstract][Full Text] [Related]
7. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
[TBL] [Abstract][Full Text] [Related]
8. Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study.
Prager W; Bee EK; Havermann I; Zschocke I
Clin Interv Aging; 2013; 8():449-56. PubMed ID: 23650444
[TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study.
Fischer T; Sattler G; Prager W; Rzany B; Pavicic T; Gauglitz G; Weissenberger P; Riaz S
J Drugs Dermatol; 2020 May; 19(5):461-469. PubMed ID: 32484631
[TBL] [Abstract][Full Text] [Related]
10. IncobotulinumtoxinA use in aesthetic indications in daily practice: a European multicenter, noninterventional, retrospective study.
Pavicic T; Prager W; Klöppel M; Ravichandran S; Galatoire O
Clin Cosmet Investig Dermatol; 2015; 8():135-42. PubMed ID: 25834463
[TBL] [Abstract][Full Text] [Related]
11. IncobotulinumtoxinA for Glabellar Frown Lines in Chinese Subjects: A Randomized, Double-blind, Active-Controlled Phase-3 Study.
Wu Y; Roll S; Klein G; Geister TL; Makara MA; Li B
Plast Reconstr Surg Glob Open; 2023 May; 11(5):e4956. PubMed ID: 37250827
[TBL] [Abstract][Full Text] [Related]
12. Different injection patterns of incobotulinumtoxinA for crow's feet: a split-face comparative study.
Vachiramon V; Subpayasarn U; Triyangkulsri K; Jurairattanaporn N; Rattananukrom T
J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):256-262. PubMed ID: 33068445
[TBL] [Abstract][Full Text] [Related]
13. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
Prager W; Rappl T
J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of incobotulinumtoxinA for treatment of glabellar frown lines: a post hoc pooled analysis of 2 randomized, placebo-controlled, phase 3 trials.
Jones D; Carruthers J; Narins RS; Coleman WP; Harrington L; Brandt FS; Cohen JL
Dermatol Surg; 2014 Jul; 40(7):776-85. PubMed ID: 25111351
[TBL] [Abstract][Full Text] [Related]
15. Evaluating an incobotulinumtoxinA and Cohesive Polydensified Matrix
Barbarino SC; Woodward JA; Levine J; Fezza J
J Cosmet Dermatol; 2021 May; 20(5):1459-1466. PubMed ID: 33051971
[TBL] [Abstract][Full Text] [Related]
16. IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines: A Prospective, Multicenter, Single-arm Study in Taiwan.
Chao YY; Tseng FW; Yang YL; Chen YH; Hsu NJ; Chang LY
J Clin Aesthet Dermatol; 2019 Dec; 12(12):E53-E57. PubMed ID: 32038766
[No Abstract] [Full Text] [Related]
17. IncobotulinumtoxinA in aesthetics: Russian multidisciplinary expert consensus recommendations.
Yutskovskaya Y; Gubanova E; Khrustaleva I; Atamanov V; Saybel A; Parsagashvili E; Dmitrieva I; Sanchez E; Lapatina N; Korolkova T; Saromytskaya A; Goltsova E; Satardinova E
Clin Cosmet Investig Dermatol; 2015; 8():297-306. PubMed ID: 26089695
[TBL] [Abstract][Full Text] [Related]
18. IncobotulinumtoxinA for Aesthetic Indications: A Systematic Review of Prospective Comparative Trials.
Prager W; Nogueira Teixeira D; Leventhal PS
Dermatol Surg; 2017 Jul; 43(7):959-966. PubMed ID: 28375973
[TBL] [Abstract][Full Text] [Related]
19. IncobotulinumtoxinA for the Treatment of Glabella and Forehead Dynamic Lines: A Real-Life Longitudinal Case Series.
da Cunha ALG; Vasconcelos R; Di Sessa D; Sampaio G; Ramalhoto P; Zampieri BF; Deus BS; Vasconcelos S; Bellote T; Carvalho J; Petrone G; Figueredo V; Limongi Moreira G
Clin Cosmet Investig Dermatol; 2023; 16():697-704. PubMed ID: 36987400
[TBL] [Abstract][Full Text] [Related]
20. Remodeling of periorbital, temporal, glabellar, and crow's feet areas with hyaluronic acid and botulinum toxin.
Beer KR; Julius H; Dunn M; Wilson F
J Cosmet Dermatol; 2014 Jun; 13(2):143-50. PubMed ID: 24910278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
